Abingworth is seeding a solid tumor-focused British immuno-oncology startup based on the work of gamma-delta T cell pioneer Adrian Hayday.

Perennial life science investors Atlas and Sofinnova have co-led a $35 million startup funding round for Delinia, a newly emerged biotech that starts life with…

Agios has filed to raise $150 million in a follow-on offering, positioning it to add to the $512 million in cash it sat on as of the end of June.

Alzheimer’s specialist AC Immune, which lists Biogen, Genentech and Johnson & Johnson among its partners, has set the terms for its long-mooted Nasdaq IPO.

A startup based on the work of gene therapy pioneer Nathalie Cartier-Lacave has secured Series A funds to advance programs against Huntington's and…

Prostate cancer biotech Advantagene has raised a little over $14 million for its experimental immune-oncology med, although it has had to use an “alternative”…

The VC wing of Novartis has joined with Fountain Healthcare Partners to lead a $17 million round in Inflazome, a chronic inflammatory disease startup.

Adienne is planning an IPO in Switzerland to fund the advance if its graft-versus-host disease drug over the regulatory finish line.

Finally following in the wake of Editas and Intellia, CRISPR Therapeutics has decided to buck the tumultuous 2016 IPO trend by going public with its highly…